a biotechnology company focused on treatments for genetic diseases, announced it will provide an update on its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) during the Eyecelerator ...

today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025 ...

(Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 ...

Patients at risk for FECD should undergo genetic screening to help assess their risk of vision loss. Genetic screening for CTG18.1 expansions can identify patients at elevated risk of vision loss ...

In addition to its GeneTAC ® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in ...